LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Company News/Bioretec Announces Scientific Advisory Board
Company News

Bioretec Announces Scientific Advisory Board

May 28, 2021 2 min read Premium comments

Advertisement

Secondary#bioretec

Tampere, Finland-based biotechnology company Bioretec Ltd. has established a scientific advisory board composed of five international professors and physicians with notable professional expertise in their fields.

Bioretec creates pediatric and adult orthopedic implants that are both “strong, safe, and reliable” and “bioabsorbable and bioresorbable.” Its newest product, the RemeOs™, is currently undergoing clinical trials. According to the website, it is a “patented bioresorbable metal” developed for “load-bearing indications.”

Bioretec Director of Marketing and Sales Lauri Hokkanen told OTW, “We aim to make an impactful change in the orthopedic industry with our new resorbable biometal. The SAB [scientific advisory board] endorses the development of our next generation RemeOs™ Screw portfolio with its comprehensive scientific and clinical experience.”

The scientific advisory board includes Prof. Dr. Klaus Dresing; Peter Giannoudis, BSc, MB, M.D., FACS, FRCS; Prof. Dr. Fan Liu; Rodrigo Pesantez, M.D.; and Prof. Dr. Endre Varga. This group will help further the clinical development of the products in the Bioretec pipeline. According to the press release, the scientific advisory board will aid in direct communication with the surgeon communities “allowing interactive knowledge transfer and sharing clinical experience.”

Prof. Dr. Klaus Dresing brings his 30 years of trauma surgery and orthopedics experience to the Bioretec scientific advisory board. He is active in the international trauma and orthopedics community and has held various leadership positions with AO Trauma. He also reviews orthopedic publications and is currently the “[h]ead and speaker of the German Society for Orthopedics and Trauma Surgery (DGOU) Guidelines Commission.”

Prof. Dr. Peter Giannoudis is a professor at United Kingdom-based University of Leeds School of Medicine and an honorary consultant at Leeds General Infirmary. He has served in numerous leadership positions with many notable groups and is currently serving as president of the European Society of Tissue Regeneration in Orthopaedics and Traumatology. According to the press release he has “almost 700 publications in peer-reviewed journals and 12 books.”

Prof. Dr. Fan Liu is the vice president, chief, and professor in the department of orthopedic surgery at the China-based Affiliated Hospital to Nantong University. Per the press release, he has over 40 years of surgical trauma experience and serves in leadership positions with the Chinese Orthopedic Association and the Chinese Association of Orthopedic Surgeons. Additionally, he is an “editor in [a] number of orthopedic journals and a globally awarded scientific researcher.”

Prof. Dr. Rodrigo Pesantez is a trauma surgeon and according to the press release he specializes in “hip, trauma and reconstruction.” His numerous leadership positions include his current role as chairperson of AO Trauma Latin America. He is also a published author in the orthopedic community.

Prof. Dr. Endre Varga is an experienced researcher in the field of bioabsorbable materials and, per the press release, has “92 scientific publications/book chapters.” He is a professor and head of the trauma department at the Hungary-based University of Szeged. He is active in the orthopedic community, serving as the Advanced Trauma Life Support (ATLS) European Committee founder and Hungarian Trauma Society past president.

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy